Abstract
The glycan-binding profile of a β-galactoside-binding 15 kDa lectin (Galectin-1) purified from the oocytes of the American bullfrog, Rana catesbeiana, was studied using 61 pyridyl-aminated oligosaccharides by frontal affinity chromatography. Human blood type-A-hexasaccharide (GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-4Galβ1-4Glc) was found to exhibit the strongest ligand binding to the galectin while Forssman antigen (GalNAcα1-3GalNAcβ1-3Galα1- 4Galβ1-4Glc) and type-A-tetrasaccharide (GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-4Glc) were also extensively recognized. The kinetics of affinity of galectin-1 to type-A oligosaccharide was analysed by surface plasmon resonance using neoglycoprotein with type-A oligosaccharides. R. catesbeiana oocyte galectin adhered to human rhabdomyosarcoma cells dose dependently and the activity was specifically cancelled by the neoglycoprotein. It was concluded that galectin-1 from R. catesbeiana oocytes possesses different and rare glycan-binding properties from typical members in galectin family.
Keywords: American bullfrog (Rana catesbeiana), blood type-A hexasaccharide, cell adhesion activity, frontal affinity chromatography, galectin-1
Protein & Peptide Letters
Title: Glycan-Binding Profile and Cell Adhesion Activity of American Bullfrog (Rana catesbeiana) Oocyte Galectin-1
Volume: 16 Issue: 6
Author(s): Sarkar M.A. Kawsar, Ryo Matsumoto, Yuki Fujii, Hidetaro Yasumitsu, Hideho Uchiyama, Masahiro Hosono, Kazuo Nitta, Jiharu Hamako, Taei Matsui, Noriaki Kojima and Yasuhiro Ozeki
Affiliation:
Keywords: American bullfrog (Rana catesbeiana), blood type-A hexasaccharide, cell adhesion activity, frontal affinity chromatography, galectin-1
Abstract: The glycan-binding profile of a β-galactoside-binding 15 kDa lectin (Galectin-1) purified from the oocytes of the American bullfrog, Rana catesbeiana, was studied using 61 pyridyl-aminated oligosaccharides by frontal affinity chromatography. Human blood type-A-hexasaccharide (GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-4Galβ1-4Glc) was found to exhibit the strongest ligand binding to the galectin while Forssman antigen (GalNAcα1-3GalNAcβ1-3Galα1- 4Galβ1-4Glc) and type-A-tetrasaccharide (GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-4Glc) were also extensively recognized. The kinetics of affinity of galectin-1 to type-A oligosaccharide was analysed by surface plasmon resonance using neoglycoprotein with type-A oligosaccharides. R. catesbeiana oocyte galectin adhered to human rhabdomyosarcoma cells dose dependently and the activity was specifically cancelled by the neoglycoprotein. It was concluded that galectin-1 from R. catesbeiana oocytes possesses different and rare glycan-binding properties from typical members in galectin family.
Export Options
About this article
Cite this article as:
Kawsar M.A. Sarkar, Matsumoto Ryo, Fujii Yuki, Yasumitsu Hidetaro, Uchiyama Hideho, Hosono Masahiro, Nitta Kazuo, Hamako Jiharu, Matsui Taei, Kojima Noriaki and Ozeki Yasuhiro, Glycan-Binding Profile and Cell Adhesion Activity of American Bullfrog (Rana catesbeiana) Oocyte Galectin-1, Protein & Peptide Letters 2009; 16 (6) . https://dx.doi.org/10.2174/092986609788490104
DOI https://dx.doi.org/10.2174/092986609788490104 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation
Current Medicinal Chemistry Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
Anti-Cancer Agents in Medicinal Chemistry Keratin-Based Biomaterials for Biomedical Applications
Current Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry mTOR Inhibition and the Tumor Vasculature
Current Angiogenesis (Discontinued) Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Bladder Conditions in Pediatric Patients: Genetics and Genomics)
Current Genomics Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts
Current Cancer Drug Targets Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design The Tumor Suppressor p53 Regulates c-Maf and Prox-1 to Control Lens Differentiation
Current Molecular Medicine Phenotypic Alteration of Bone Marrow HSC and Microenvironmental Association in Experimentally Induced Leukemia
Current Stem Cell Research & Therapy Bioinformatics and Drug Discovery
Current Topics in Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets